Alexander E Perl

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Exploiting signal transduction pathways in acute myelogenous leukemia
    Alexander E Perl
    Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA, USA
    Curr Treat Options Oncol 8:265-76. 2007
  2. pmc Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy
    Alexander E Perl
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Clin Cancer Res 18:1716-25. 2012
  3. doi request reprint A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
    Alexander E Perl
    Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 15:6732-9. 2009
  4. doi request reprint A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia
    Donald E Tsai
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 14:5619-25. 2008
  5. doi request reprint Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens
    Daniel J Landsburg
    Division of Hematology Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    Am J Hematol 88:657-60. 2013
  6. pmc Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
    Courtney D DiNardo
    University of Pennsylvania, Philadelphia, PA 19146, USA
    Blood 121:4917-24. 2013
  7. pmc Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
    Catherine C Smith
    Division of Hematology Oncology, University of California, San Francisco, California 94143, USA
    Nature 485:260-3. 2012

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Exploiting signal transduction pathways in acute myelogenous leukemia
    Alexander E Perl
    Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA, USA
    Curr Treat Options Oncol 8:265-76. 2007
    ....
  2. pmc Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy
    Alexander E Perl
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Clin Cancer Res 18:1716-25. 2012
    ..However, we did not reliably determine the extent of mTOR inhibition on that study. Here, we sought to develop an assay that allowed us to serially quantify the activation state of mTOR kinase during therapy...
  3. doi request reprint A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
    Alexander E Perl
    Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 15:6732-9. 2009
    ..We sought to determine the safety and describe the toxicity of this approach by adding the mTOR inhibitor, sirolimus (rapamycin), to intensive AML induction chemotherapy...
  4. doi request reprint A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia
    Donald E Tsai
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 14:5619-25. 2008
    ..We therefore conducted a phase I dose escalation study to assess the maximum tolerated dose, toxicities, and activity of bexarotene in patients with non-M3 acute myeloid leukemia (AML)...
  5. doi request reprint Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens
    Daniel J Landsburg
    Division of Hematology Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    Am J Hematol 88:657-60. 2013
    ..Our analysis reveals the benefit of prolonged therapy in the treatment of older adults with ALL as well as the high incidence of treatment-related toxicity experienced by these patients...
  6. pmc Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
    Courtney D DiNardo
    University of Pennsylvania, Philadelphia, PA 19146, USA
    Blood 121:4917-24. 2013
    ....
  7. pmc Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
    Catherine C Smith
    Division of Hematology Oncology, University of California, San Francisco, California 94143, USA
    Nature 485:260-3. 2012
    ..Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML. AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts...